Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Psoriasis Biosimilars Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The psoriasis biosimilars market has experienced rapid expansion over the last few years. From $8.16 billion in 2025, it is forecasted to reach $9.08 billion by 2026, reflecting an 11.3% compound annual growth rate (CAGR). Historically, this growth has been driven by the expensive nature of reference biologics, restricted patient access to therapies, a rising incidence of moderate to severe psoriasis, heightened physician awareness and prescription rates, and the initial regulatory approvals given to TNF-alpha inhibitors.
The market for psoriasis biosimilars is projected to experience rapid expansion in the coming years, reaching an estimated value of $13.79 billion by 2030, with a compound annual growth rate (CAGR) of 11.0%. This anticipated growth during the forecast period is driven by factors such as the introduction of new biosimilars for drugs like infliximab, etanercept, and adalimumab, the broadening of hospital-based and online pharmacy networks, an increase in dermatological healthcare spending, expanded use of patient assistance programs, and a rising number of clinical trials focused on innovative biosimilars. Key trends expected to shape this period include a growing preference for cost-effective psoriasis biosimilars, a heightened emphasis on patient accessibility and affordability, the expansion of both subcutaneous and intravenous administration methods, the broadening of distribution networks through hospitals and retail pharmacies, and the creation of targeted therapies designed for various forms of psoriasis.
Download A Free Sample Report For Comprehensive Market Insights:
Psoriasis Biosimilars Market Opportunity Drivers: What Is Creating New Revenue Potential?
The anticipated expansion of the psoriasis biosimilars market is being driven forward by increasing diagnosis rates of psoriatic arthritis. This condition is a chronic autoimmune disorder characterized by inflammation affecting both the joints and the skin, most commonly seen in individuals who have a history of psoriasis. Detection rates are climbing, largely due to improved screening practices for psoriasis patients, enabling earlier identification and more precise diagnosis by picking up on subtle joint symptoms that were previously missed. Psoriasis biosimilars offer a cost-effective substitute for biologic treatments, effectively decreasing joint inflammation and skin manifestations associated with psoriatic arthritis. According to the National Psoriasis Foundation (NPF), a non-profit patient advocacy group based in the United States, roughly one out of every three people with psoriasis also suffers from psoriatic arthritis, with as many as 2.4 million Americans affected—and over 15% of psoriasis patients may have undiagnosed psoriatic arthritis, underscoring both heightened awareness and ongoing gaps in detection. As a result, the rising prevalence of diagnosed psoriatic arthritis is fueling growth in the psoriasis biosimilars market.
Psoriasis Biosimilars Market Segment Analysis: What Are The Major Market Categories?
The psoriasis biosimilars market covered in this report is segmented –
1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars
Psoriasis Biosimilars Market Innovation Trends Driving Future Development
Key players within the psoriasis biosimilars market are prioritising the development of cutting-edge options, specifically biosimilars designed for plaque psoriasis, to broaden treatment availability, cut healthcare expenses, and boost patient outcomes. These biosimilars, which are affordable and highly comparable to sanctioned biologic therapies, address the chronic autoimmune disorder characterised by inflamed, scaly skin patches. In May 2025, for instance, Sandoz Group AG, a Swiss firm dedicated to generic drugs and biosimilars, unveiled the Pyzchiva autoinjector—the first commercially accessible ustekinumab biosimilar autoinjector. This product has received approval for managing plaque psoriasis in adults, psoriatic arthritis, Crohn’s disease, and paediatric patients aged six and older (with a weight exceeding 60 kg) suffering from plaque psoriasis. Crafted to improve patient compliance and well-being, the autoinjector offers precise automatic dosing, minimised injection discomfort, a sleek build, and adaptable storage solutions to facilitate more convenient self-administration.
Psoriasis Biosimilars Market Leading Companies Driving Competitive Growth
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.
Access The Complete Psoriasis Biosimilars Market Report:
Psoriasis Biosimilars Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model